Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilocarpine - Orasis Pharmaceuticals

Next Previous
X
Search
Drug Profile

Pilocarpine - Orasis Pharmaceuticals

Alternative Names: CSF -1- low dose pilocarpine hydrochloride 0.4%; CSF-1 - Orasis Pharmaceuticals; Pilocarpine hydrochloride ophthalmic solution; PresbiDrops; PresbiDrops (CSF-1); Qlosi

Latest Information Update: 18 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orasis Pharmaceuticals
  • Class Alkaloids; Antiglaucomas; Eye disorder therapies; Furans; Imidazoles; Ketones; Miotics; Small molecules
  • Mechanism of Action Muscarinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Presbyopia

Most Recent Events

  • 16 Oct 2024 Pilocarpine licensed to Optus Pharmaceuticals in South Korea
  • 16 Oct 2024 Orasis Pharmaceuticals plans to launch Pilocarpine (Qlosi™) in Korea by December 2026
  • 18 Oct 2023 Orasis pharmaceuticals plans to launch Pilocarpine hydrochloride ophthalmic solution 0.4% for treatment of presbyopia in the US by H1 of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top